Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions highlight a mix of supportive and concerned sentiments regarding the M72/AS01E vaccine, with phrases like 'game changer' indicating excitement over the vaccine's 54% efficacy against tuberculosis, while others express caution about risks, with comments such as 'don’t treat casualties as mere statistics.' This combination reveals a nuanced understanding of both the potential benefits and concerns, showcasing a balanced tone in the overall conversation.
There is general support for the findings of the publication, although some participants are cautious about the safety and risks involved.
The posts reflect a high level of curiosity regarding the vaccine's efficacy and implications, indicating that many are closely following ongoing discussions.
Several users engage with the research details and express their views on the implications for public health, although not every discussion dives deeply into the scientific aspects.
Many participants perceive the results as having significant potential to impact tuberculosis prevention, highlighting its importance in addressing a persistent health threat.
@richardhirschs1 Yeah after reading up on the new vaccines, I think I’ll wait for this to finish the Phase III trial: https://t.co/s4JMqvM9WV.
@georgebest1969 @minesoh @ishidesu00 純粋に結核に対する効果と地域罹患率だけの評価なら私も悩みましたが、親が医療従事者、結核以外の非特異的効果、高齢者以外の外国人患者の増加、日本が中等度蔓延国で努力義務あり等 総合的に勘案してBCG接種させました 成人用には良いワクチンが開発されつつありますね https://t.co/isOLDRgpiD
نتائج تجربة عملية سريرية شملت ٣٥٧٥ شخصاً من كينيا،جنوب أفريقيا وزامبيا ونشرتها NEJM تظهر فعالية لقاح جديد في الوقاية من مرض السل الرئوي لمدة ٣ سنوات على الأقل. https://t.co/BR67Kg0JoT
Beyond pleased to be a part of the next steps for this #vaccine research. @GatesMRI looks to a future without #tuberculosis. #EndTB https://t.co/O2A7ePLybC
Among adults infected with Mycobacterium #tuberculosis, vaccination with M72/AS01E elicits immune responses and provide protection against progression to #pulmonary tuberculosis disease for at least 3 years. #TB https://t.co/tHDpIu2DiH
Uji coba vaksin TB M72/AS01E fase: - 1. selesai 2016 - 2b. 2018-2019 - 3. Maret 2024-Agustus 2029. 47 kematian, 19 peserta (1,1%) dr 1,786. 28 peserta (1,6%) dr 1.787 dlm kelompok plasebo. Efikasi vaksin 54% thd TB paru dan respons imun vaksi slm 3 thn. https://t.co/QuF1JU5udi
RT @hanan052020: @junlearnscrypto itu fase 2 belum fase 3 Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis | New Eng…
RT @hanan052020: @junlearnscrypto itu fase 2 belum fase 3 Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis | New Eng…
RT @hanan052020: @junlearnscrypto itu fase 2 belum fase 3 Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis | New Eng…
RT @VFathun: @ArmyDaud https://t.co/saNWWkbubQ
RT @VFathun: @quenepaberry @TedInvestigasi https://t.co/saNWWkbubQ
@quenepaberry @TedInvestigasi https://t.co/saNWWkbubQ
RT @VFathun: @ArmyDaud https://t.co/saNWWkbubQ
@ArmyDaud https://t.co/saNWWkbubQ
RT @hanan052020: @junlearnscrypto itu fase 2 belum fase 3 Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis | New Eng…
@junlearnscrypto itu fase 2 belum fase 3 Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis | New England Journal of Medicine https://t.co/GX2VXVzNAv
@TxtdariHI Semoga saja dari tim peneliti jujur resiko apa saja yg bisa terjadi pada partisipan, termasuk kemungkinan kematian. (Lihat link) Jangan dianggap korban sebagai angka statistik Teringat berita masa covid ada yg demam dan meninggal setelah disuntik vaksin https://t.co/gs5AKAm9VX https://t.co/FG6TGP4DCW
RT @gwangge: @yanuarnugroho Silahkan pak ditakar risiko-nya (safety concern) via publikasi Phase 2 vaksinnya https://t.co/VtRleab1M3
@yanuarnugroho Silahkan pak ditakar risiko-nya (safety concern) via publikasi Phase 2 vaksinnya https://t.co/VtRleab1M3
RT @drseanmullen: @richardhirschs1 Yeah after reading up on the new vaccines, I think I’ll wait for this to finish the Phase III trial: ht…
RT @drseanmullen: @richardhirschs1 Yeah after reading up on the new vaccines, I think I’ll wait for this to finish the Phase III trial: ht…
@richardhirschs1 Yeah after reading up on the new vaccines, I think I’ll wait for this to finish the Phase III trial: https://t.co/s4JMqvM9WV.
@IntegralAnswers @GoviThom25304 I know of the BCG vaccine and then there is this one. I haven’t seen an update of it in a while. https://t.co/qfShTlCYuR
Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis | New England Journal of Medicine https://t.co/gkNcxakJuJ
This is massively exciting, especially given the promising results from the phase 2b trial published in 2019 - 50% efficacy over 3 years https://t.co/7jd3elP99B
7. Overall 40% ⬇️hazard TB (caveat: concerns above may have inflated effect size) & reassuring to see effect when restrict to micro-pos disease
で、今回の新型ワクチン。 原著は2019年のNEJMの論文（たぶん）。 GlaxoSmithKlineの組み換えタンパクワクチンM72/AS01E。 アフリカで行った3289人のphaseII RCTで結核既感染の成人（潜伏感染）の、活動性肺結核発症を54%予防することに成功した。 DOI: 10.1056/NEJMoa1909953
RT @KJ47468238: @liz_churchill10 2 posts "In brief, this double-blind, randomized, placebo-controlled trial was conducted in three African…
@liz_churchill10 2 posts "In brief, this double-blind, randomized, placebo-controlled trial was conducted in three African countries"... https://t.co/a1bT91DFyR https://t.co/82BrNH6KhZ
@petermbenglish @lizWWyld @BeateKampmann @WHO And here is the final analysis of a trial of M72/AS01E TB vaccine: https://t.co/WmleQ9NMqf
@drpriono1 Ada dok, sudah selesai fase 2 https://t.co/RynOzFTlEa
MESA-TB follows a previous study of the M72/AS01[E] TB vaccine, which found that the vaccine reduced the rate of TB lung disease in HIV-ve adults by half. https://t.co/RZLce5J7O8
RT @TheCrick:
Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis https://t.co/LKvL3TX6Nn
予想しているものとは違うかもしれないけど、結核に対するワクチン https://t.co/10goSjdFT1
Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis | NEJM 2019-12-19 https://t.co/Iky2Vr8jQM Immunogenicity and Safety of the M72/AS01E Candidate Vaccine Against Tuberculosis: A Meta-Analysis 2019-09-03 https://t.co/5AllXaD7Eo
RT @NLTb_JC: It's almost JC time ! @MSF_uk @docwak77 If you can't join us in person at 4pm, join us via video link: https://t.co/8B0PDTq8gp…
It's almost JC time ! @MSF_uk @docwak77 If you can't join us in person at 4pm, join us via video link: https://t.co/8B0PDTq8gp Paper can be found here: https://t.co/a4yXb82c9Z
The results of the 3-year final analysis of efficacy, safety, and immunogenicity
RT @drpennyheaton: Beyond pleased to be a part of the next steps for this #vaccine research. @GatesMRI looks to a future without #tuberculo…
Beyond pleased to be a part of the next steps for this #vaccine research. @GatesMRI looks to a future without #tuberculosis. #EndTB https://t.co/O2A7ePLybC
the vaccine actually caused more illness than should have occurred if the subjects had no injections. https://t.co/zUtZjqq8bz
【NEJM 2019.12：RCT】結核高度蔓延国のIGRA陽性者に対する結核不活化ワクチンの活動性肺結核の予防効果は約50%だった。2回接種（1回0.5ml、筋注、1か月間隔）。 https://t.co/OT6s1Eqgyq
Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis | NEJM https://t.co/qjIDtWSs6O
RT @Fredros_Inc: Among adults infected with Mycobacterium #tuberculosis, vaccination with M72/AS01E elicits immune responses and provide pr…
Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis | NEJM https://t.co/mUBzzH0TwB
RT @Fredros_Inc: Among adults infected with Mycobacterium #tuberculosis, vaccination with M72/AS01E elicits immune responses and provide pr…
Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis | NEJM https://t.co/lrodpYAdR1
Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis | NEJM #vaccine #tuberculosis #medicine #WomenInMedicine #research #innovation https://t.co/VHe4i0481i
Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis | NEJM https://t.co/dWZ0uTpbet
El principio del fin de la #Tuberculosis ??? https://t.co/tZQhMBgxFK https://t.co/hOuPpIF9yO
RT @Fredros_Inc: Among adults infected with Mycobacterium #tuberculosis, vaccination with M72/AS01E elicits immune responses and provide pr…
RT @Fredros_Inc: Among adults infected with Mycobacterium #tuberculosis, vaccination with M72/AS01E elicits immune responses and provide pr…
Among adults infected with Mycobacterium #tuberculosis, vaccination with M72/AS01E elicits immune responses and provide protection against progression to #pulmonary tuberculosis disease for at least 3 years. #TB https://t.co/tHDpIu2DiH
TB is still a leading cause of death and this vaccine prevents active TB in half the patients treated @UofT_dlsph @PublicHealthON @picardonhealth Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis | NEJM https://t.co/4MmOHdBIU6
RT @mencardio: Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis | NEJM https://t.co/CLbTOfJf1X
Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis | NEJM https://t.co/zAOJknHuUf
Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis | NEJM https://t.co/FI0Rb0KvfG
RT @carpe_diem0820: @georgebest1969 @minesoh @ishidesu00 純粋に結核に対する効果と地域罹患率だけの評価なら私も悩みましたが、親が医療従事者、結核以外の非特異的効果、高齢者以外の外国人患者の増加、日本が中等度蔓延国で努力義務…
RT @carpe_diem0820: @georgebest1969 @minesoh @ishidesu00 純粋に結核に対する効果と地域罹患率だけの評価なら私も悩みましたが、親が医療従事者、結核以外の非特異的効果、高齢者以外の外国人患者の増加、日本が中等度蔓延国で努力義務…
@georgebest1969 @minesoh @ishidesu00 純粋に結核に対する効果と地域罹患率だけの評価なら私も悩みましたが、親が医療従事者、結核以外の非特異的効果、高齢者以外の外国人患者の増加、日本が中等度蔓延国で努力義務あり等 総合的に勘案してBCG接種させました 成人用には良いワクチンが開発されつつありますね https://t.co/isOLDRgpiD
Entre los adultos infectados con M. tuberculosis, la vacunación con M72 / AS01E provocó una respuesta inmune y proporcionó protección contra la progresión a la enfermedad de tuberculosis pulmonar durante al menos 3 años. https://t.co/X0PkNWbXHg
RT @haaa78D: نتائج تجربة عملية سريرية شملت ٣٥٧٥ شخصاً من كينيا،جنوب أفريقيا وزامبيا ونشرتها NEJM تظهر فعالية لقاح جديد في الوقاية من مرض…
RT @haaa78D: نتائج تجربة عملية سريرية شملت ٣٥٧٥ شخصاً من كينيا،جنوب أفريقيا وزامبيا ونشرتها NEJM تظهر فعالية لقاح جديد في الوقاية من مرض…
RT @haaa78D: نتائج تجربة عملية سريرية شملت ٣٥٧٥ شخصاً من كينيا،جنوب أفريقيا وزامبيا ونشرتها NEJM تظهر فعالية لقاح جديد في الوقاية من مرض…
RT @haaa78D: نتائج تجربة عملية سريرية شملت ٣٥٧٥ شخصاً من كينيا،جنوب أفريقيا وزامبيا ونشرتها NEJM تظهر فعالية لقاح جديد في الوقاية من مرض…
RT @haaa78D: نتائج تجربة عملية سريرية شملت ٣٥٧٥ شخصاً من كينيا،جنوب أفريقيا وزامبيا ونشرتها NEJM تظهر فعالية لقاح جديد في الوقاية من مرض…
RT @haaa78D: نتائج تجربة عملية سريرية شملت ٣٥٧٥ شخصاً من كينيا،جنوب أفريقيا وزامبيا ونشرتها NEJM تظهر فعالية لقاح جديد في الوقاية من مرض…
نتائج تجربة عملية سريرية شملت ٣٥٧٥ شخصاً من كينيا،جنوب أفريقيا وزامبيا ونشرتها NEJM تظهر فعالية لقاح جديد في الوقاية من مرض السل الرئوي لمدة ٣ سنوات على الأقل. https://t.co/BR67Kg0JoT
Mycobacterium tuberculosis sigue siendo una gran amenaza para la salud pública. En este informe, la vacuna M72 / AS01E proporcionó aproximadamente un 50% de protección contra la progresión a la enfermedad activa en adultos. https://t.co/Iz16UX8mc2
Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis | NEJM https://t.co/CLbTOfJf1X
RT @Sander_Lab: Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis @NEJM 49.7% Vaccine efficacy to prevent open pulmon…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis | NEJM https://t.co/jHcrUBmje5
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @jsherkow: A *major* step in developing a TB vaccine https://t.co/WdkyGCXY21
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
RT @NEJM: Mycobacterium tuberculosis remains a major global health threat. In this report, the M72/AS01E vaccine provided approximately 50%…
Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis | NEJM https://t.co/mV8zG5fICN
RT @TheCrick:
RT @TheCrick:
RT @TheCrick:
RT @TheCrick:
RT @TheCrick:
RT @TheCrick:
RT @ImperialInfect: Take a look at the results in full via @NEJM
RT @ImperialInfect: Take a look at the results in full via @NEJM
Take a look at the results in full via @NEJM
.@NEJM NEJM: Final Analysis of a Trial of M72/AS01E #Vaccine to Prevent #Tuberculosis https://t.co/65VtGqNCjS https://t.co/CpSi8W04j7
DM
TI
M無
هA
PH
FO
B
FP
L
EP
A
H
OP
DA
RP
AH
YN
GI
PB
SP
MD
LM
JB
HR
T
K
K
V
DD
CS
M
ヨ
Y
堀
TY
TC
BV
GI
っP
H感
SE
نم
T
JG
JN
P
Y
JE
GO
MB
ER
?
K固
YV
DA
فA
عم
YA
S
وا
FC
IM
SP
RR
SC
GR
R
A
AM
TA
MS
DO
C
AJ
IF
F
A
B
HP
LA
TN
AC
HG
AM
A
MM
NG
HR
RG
MF
LA
LC
BC
SA
PQ
ID
CN
DP
E
MG
EW
GC
GF